Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients
Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients
复制标题
DOI：
10.21873/anticanres.11932
复制
发表时间：
2017-09-01
影响因子：
2
通讯作者：
Niimi, Akio
中科院分区：
文献类型：
--
作者：
Sone, Kazuki;Oguri, Tetsuya;Niimi, Akio
背景/目的：本研究的目的是确定肿瘤标志物水平对既往接受过治疗的NSCLC患者的临床价值。患者和方法：我们回顾性筛选了113例既往接受过多西他赛单药治疗的晚期NSCLC患者，检测其治疗前血清细胞角蛋白19片段（CYFRA 21 -1）和癌胚抗原（CEA）水平。结果如下：32名CYFRA 21 -1水平正常且CEA水平高的患者的缓解率明显高于其他81名患者（25%比8.6%，p= 0.031）。前一组的无进展生存期（PFS）和总生存期（OS）在统计学上长于后一组（中位PFS，180 vs. 59天，p< 0.001;中位OS，579 vs. 255天，p= 0.002）。在多变量分析中，肿瘤标志物水平对PFS和OS有显著影响。结论：两种肿瘤标志物的组合是多西他赛单药治疗NSCLC患者的预测和预后标志物。
Background/Aim: The aim of the present study was to determine the clinical value of tumor marker levels for previously treated NSCLC patients. Patients and Methods: We retrospectively screened 113 previously treated patients with advanced NSCLC who were treated with docetaxel monotherapy regarding the pretreatment serum level of cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA). Results: The thirty-two patients with normal CYFRA21-1 levels and high CEA levels had a significantly higher response rate than the other 81 patients (25% vs. 8.6%, p= 0.031). The former group showed statistically longer progression-free survival (PFS) and overall survival (OS) than the latter group (median PFS, 180 vs. 59 days, p< 0.001; median OS, 579 vs. 255 days, p= 0.002). In multivariate analysis, tumor marker levels had a significant impact on PFS and OS. Conclusion: Combination of the two tumor markers is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients.